S'abonner

Clinical benefits of autologous haematopoietic stem cell transplantation in type 1 diabetes patients - 05/09/18

Doi : 10.1016/j.diabet.2017.12.006 
B. Gu a, 1, H. Miao a, 1, J. Zhang a, 1, J. Hu b, W. Zhou a, W. Gu a, , W. Wang a, , G. Ning a, c
a Department of endocrine and metabolic diseases, Ruijin hospital, Shanghai Jiao-Tong university, school of medicine, Shanghai Key laboratory for endocrine tumours, Shanghai clinical centre for endocrine and metabolic diseases, Shanghai institute of endocrine and metabolic diseases and Shanghai E-institute for endocrinology, Shanghai, China 
b Department of haematology, Ruijin hospital, Shanghai Jiao-Tong university, school of medicine, Shanghai, China 
c Laboratory for endocrine & metabolic diseases, institute of health science, Shanghai JiaoTong university, school of medicine and Shanghai institutes for biological sciences, Chinese academy of sciences, Shanghai, China 

Corresponding author at: No. 197, Ruijin Er Road, Shanghai Ruijin Hospital, Shanghai 200025. P.R. China.No. 197, Ruijin Er Road, Shanghai Ruijin Hospital, Shanghai 200025. P.R. China.⁎⁎Co-corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Type 1 diabetes (T1D) is characterized by severe damage to pancreas islet function through immunological attack; therefore, it is also called ‘insulin-dependent diabetes’. The present study aimed to evaluate the safety and clinical efficacy of autologous haematopoietic stem cell transplantation (AHSCT) in adolescent patients with newly diagnosed T1D. A phase-II prospective, parallel-assignment, non-randomized trial was conducted from March 2008 to December 2011 with 40 T1D patients, of whom 20 received AHSCT therapy and 20 were treated only with insulin injections. Of these patients, 14 (70%) in the AHSCT group became insulin-independent for 1.5 to 48 months compared with only one patient in the Insulin group. Of these 14 AHSCT patients, 11 relapsed within a median time of 19.5 (range 5.5–1) months and resumed insulin use. By the end of the 4-year follow-up, the difference in daily insulin dosages between the AHSCT and Insulin groups had become smaller (0.49±0.32IU/kg/day vs. 0.79±0.18IU/kg/day, respectively; P<0.01). C-peptide levels increased significantly at 3 months in both groups and later decreased, with the insulin group showing more rapid deterioration. Most of the adverse events in the AHSCT group were transplantation complications. Our data suggest that AHSCT treatment was well tolerated and slowed deterioration of islet β-cell function while significantly decreasing daily insulin dosages. However, because of the high relapse rate, more information on longer-term outcomes is needed before AHSCT can be routinely considered for T1D patients. Significance: although this was a non-randomized clinical study, this phase-II trial demonstrated the beneficial effects of AHSCT in patients with newly diagnosed T1D by increasing C-peptide levels and inducing insulin independence, while showing its safety and good tolerability compared with conventional intensive insulin therapy. Thus, these results are helpful for increasing our understanding of the use of haematopoietic stem cell therapy in the treatment of T1D and for evaluating whether it can become more widespread in future.

Le texte complet de cet article est disponible en PDF.

Keywords : Cell therapy, Insulin therapy, Haematopoietic stem cell, Type 1 diabetes


Plan


© 2017  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 44 - N° 4

P. 341-345 - septembre 2018 Retour au numéro
Article précédent Article précédent
  • Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events
  • M.C. Riddle, G.B. Bolli, A. Avogaro, M. Gimenez Álvarez, A. Merino-Trigo, E. Boëlle-Le Corfec, P.D. Home
| Article suivant Article suivant
  • Total serum bilirubin and 8-year incident type 2 diabetes mellitus: The Korean Genome and Epidemiology Study
  • Y.-J. Kwon, Y.-J. Lee, B.-J. Park, K.-W. Hong, D.-H. Jung

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.